CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation AIM2-driven inflammasome activation in heart failure Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Expert Opinion2020 Oct 14;41(39):3769-3773.

JOURNAL:Eur Heart J. Article Link

The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions

F Crea. Keywords: HF; non-pharmacological interventions; mechanisms

Full Text PDF